title: Hypnotic self administration: forced-choice versus single-choice.
abstract: Twenty-four men and women with insomnia, age 21-50 years, self administered hypnotics under a single-choice with placebo, single-choice with triazolam (0.25 mg), or forced-choice of placebo versus triazolam (0.25 mg) paradigm. Subjects received 4- sampling nights of placebo or triazolam in the single-choice conditions or 2 nights of each in the forced-choice condition. Then on 7 choice nights they could self administer a capsule, or not, in the single-choice conditions, or were required to choose one of two color-coded capsules in the forced-choice condition. In the single-choice conditions, subjects chose placebo 80% of nights and triazolam 77% of nights, while in the forced-choice condition triazolam was chosen on 86% of nights. Thus, the self administration of triazolam did not vary significantly between single or forced choice conditions, but that of placebo did. Placebo rate was high when it was the only alternative, but low when competing with triazolam. On sampling nights, compared to placebo, triazolam produced a significant increase in total sleep time, a reduction in latency to sleep, wake after sleep onset, and percentage stage 1 sleep. Triazolam, relative to placebo, also improved mood in the morning on some sampling nights. For subjects choosing capsules < 100% of opportunities (n = 14), on nights a capsule was chosen versus nights none was chosen (regardless of whether placebo or triazolam was the choice), self-ratings 30 min before bedtime on the Profile of Mood States vigor scale were significantly higher.
authors.affiliation: Henry Ford Hospital, Sleep Disorders and Research Center, Detroit, MI 48202, USA.
authors.forename: T
authors.initials: T
authors.lastname: Roehrs
authors.forename: B
authors.initials: B
authors.lastname: Pedrosi
authors.forename: L
authors.initials: L
authors.lastname: Rosenthal
authors.forename: F
authors.initials: F
authors.lastname: Zorick
authors.forename: T
authors.initials: T
authors.lastname: Roth
mesh_terms: D000328:Adult; D000339:Affect / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012646:Self Administration; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D012894:Sleep Stages / Q000187:drug effects; D014229:Triazolam / Q000627:therapeutic use*
chemical_list: D006993:Hypnotics and Sedatives; D014229:Triazolam